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This study reports the results of a questionnaire survey of female members of the British Epilepsy Association (BEA). The women
were asked about their concerns about their epilepsy with respect to being female, and, in particular, asked about the information
they had been given on important topics such as contraception and pregnancy. A questionnaire was sent to 6000 BEA female
members of whom 1855 (31 %) replied. Forty-six percent of the women (mainly aged between 26 and 45) stated that they currently
used some form of contraception. The most frequently used method was the condom (34 %). Twenty-two percent of the women
using contraception were taking the oral contraceptive pill whilst a further 4 % were using a hormonal contraceptive injection.
Fifty-one percent of the women aged between 16 and 55 claimed not to have received any advice about possible interactions
between contraception and antiepileptic drug therapy. With regards to pregnancy, 34 % claimed they had not received any advice
and 25 % had not discussed pregnancy with anyone. The women planning to have children over the subsequent 2 years received
the greatest amount of advice about epilepsy and pregnancy, although 20 % still claimed not to have received any information.
Thirty-four percent of the women in the study stated that they were either menopausal or post-menopausal. Twenty-nine percent
of women who had taken hormone replacement therapy in the past reported an increase in seizure frequency compared with
18 % amongst current users. This survey has shown that women with epilepsy want, and need, more information and counselling
about issues relating to contraception, pregnancy and the menopause.
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Until recently, the management of patients with
seizures took no account of gender, despite the fact
that about 50 % of people with epilepsy are female.
Epilepsy for a woman is not the same as epilepsy for
a man. In particular, in women, epilepsy affects sex-
ual development, sexuality, the menstrual cycle, as-
pects of contraception, fertility, the developing foetus
and pregnancy, the mother–child relationship and the
menopause, in ways that are unique to their sex. There-
fore, the British Epilepsy Association (BEA) undertook
a survey of its female members, asking about their con-
cerns about their epilepsy with respect to being female,
and in particular asking about the information they had
received on important topics such as contraception and
pregnancy.
Materials and Methods
A questionnaire was designed in consultation with
Taylor Nelson Sofres Healthcare, an independent1059–1311/99/030135 + 05 $12.00/0market research agency, and was sent to 6000 BEA
female members. Not all these women would have had
epilepsy, some would have been carers, others friends,
etc. Only females with epilepsy aged 16 or above were
asked to fill in the questionnaire. This questionnaire
was devised following qualitative research with women
with epilepsy that was conducted by Taylor Nelson
Sofres Healthcare.
Results
Data in the study are based on the 1855 (31 %) ques-
tionnaires which were returned by the cut-off date for
inclusion in the study.
Patient demographics
The age of the respondents is summarized in Table 1,
their treatment in Table 2 and the length of time since
onset of their epilepsy in Table 3.c© 1999 BEA Trading Ltd
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Table 1: Age of patients .n D 1885/.
Under 16 27 (1 %)
16–25 260 (14 %)
26–35 497 (26 %)
36–45 419 (23 %)
46–55 385 (21 %)
Over 55 265 (14 %)
Not stated 2
Table 2: Antiepileptic drug therapy .n D 1885/.
Phenobarbitone 87 (5 %)
Phenytoin 300 (16 %)
Carbamazepine/Tegretol SR 835 (47 %)
Sodium valproate/Epilim retard 635 (32 %)
Lamotrigine 341 (18 %)
Gabapentin 111 (6 %)
Vigabatrin 78 (4 %)
Topiramate 77 (4 %)
Clobazam 130 (7 %)
Monotherapy 1102 (59 %)
Table 3: Length of time since diagnosis .n D 1885/.
Age (years) n
<2 185 10%
3–5 251 13%
5–10 328 18%
11–20 459 25%
21–30 292 16%
31–40 197 11%
>40 80 4%
Table 4: Marital Status .n D 1885/.
Married/living with partner 1107 (60 %)
Single 531 (29 %)
Divorced/separated/widowed 184 (10 %)
Not stated 33 (2 %)
Table 5: Methods of contraception used by women using
contraception .n D 847/.
Condom 290 (34 %)
Oral contraceptive pill 189 (22 %)
IUD 77 (9 %)
Vasectomy 59 (7 %)
Tubal ligation/hysterectomy 81 (10 %)
Depot injection 40 (4 %)Of the women, 1276 (64 %) were of child-bearing
age, i.e. between the ages of 16 and 45. The marital sta-
tus of the respondents is summarized in Table 4. Eight
hundred and eighty (47 %) women had had children:
292 (17 %) currently had children under the age 10.
One thousand and ninety-three (59 %) women were
attending a hospital clinic for their epilepsy.
Contraception
Eight hundred and forty-seven (46 %) women (mainly
aged between 26 and 45) stated that they currently used
some form of contraception (Table 5). The most fre-
quently used method was the condom (290 (34 %) of
those using contraception). One hundred and eighty-
nine (22 %) of the women using contraception were
taking the oral contraceptive pill, whilst a further
40 (4 %) were using a hormonal contraceptive in-
jection. Amongst the women using contraception, 83
(16 %) women on enzyme-inducing antiepileptic drugs
were taking the oral contraceptive pill compared with
130 (27 %) on non-enzyme-inducing antiepileptic drug
therapy.
General practitioners and hospital specialists were
equally likely to provide information regarding contra-
ception. However, 948 (51 %) women claimed not to
have received any advice about possible interactions
between contraception and antiepileptic drug therapy
(Table 6).Of those using the oral contraceptive pill .n D 189/,
31 (16 %) claimed not to have been given any advice
whilst 81 (43 %) of the women indicated they had been
given information regarding reduced effectiveness of
the contraceptive pill (Table 7). Sixty-nine women
(37 %) on the oral contraceptive pill were taking an
increased dose, and 32 (17 %) of these women stated
that they were concerned about taking this higher
dose. Eighty-nine (47 %) women taking the oral con-
traceptive pill felt that they had not been given enough
information about the contraceptive pill and their med-
ication.
Pregnancy
Eight hundred and eighty (47 %) of the women al-
ready had children, but one in 10 of these were plan-
ning to have further children. Overall, 441 (23 %) of
the women were planning to have children, 169 (9 %)
within the next 2 years (Table 8).
The women were asked about the advice they had
received about pregnancy (Table 9). Six hundred and
thirty-seven (34 %) claimed they had not received any
advice and 459 (25 %) had not discussed pregnancy
with anyone. Amongst those who had already had chil-
dren, 232 (38 %) claimed not to have received any ad-
vice about pregnancy and epilepsy and only 210 (24 %)
had discussed the issues with a doctor before con-
ception. The women planning to have children over
the subsequent 2 years received the greatest amount
of advice about epilepsy and pregnancy, although 34
(20 %) still claimed not to have received any advice.
Many women intending to have children in the next
2 years felt they still had unanswered questions relat-
ing to their epilepsy and pregnancy and subsequent care
of the child (Table 10). The best informed group com-
prised those women who had already had children and
planned to have more.
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Table 6: Advice about contraception given to women.
Advice All women Women using contraception
.n D 1885/ .n D 847/
Advised not to take oral contraceptive pill 316 (17 %) 68 (8 %)
Told about reduced efficacy of oral contraceptive pill 490 (26 %) 218 (26 %)
Told that a higher dose oral contraceptive pill was required 97 (5 %) 67 (8 %)
Told current medication may limit effectiveness of oral contraceptive pill 135 (7 %) 118 (14 %)
Told to take additional contraception precautions 20 (1 %) 16 (2 %)
No advice given 948 (51 %) 207 (24 %)
Table 7: Advice about the oral contraceptive pill given to women taking the oral contraceptive pill.
Advice All women Women taking enzyme
on oral contraceptive pill inducing antiepileptic drugs
.n D 189/ .n D 83/
Told about reduced efficacy of oral contraceptive pill 81 (43 %) 48 (58 %)
Told that a higher dose oral contraceptive pill was required 34 (18 %) 21 (25 %)
Told current medication may limit effectiveness of oral contraceptive pill 41 (22 %) 24 (29 %)
Told to take additional contraception precautions 7 (4 %) 9 (11 %)
No advice given 31 (16 %) 9 (11 %)
Table 8: Women’s intentions about children .n D 1885/.
Already have children 880 (45 %)
Planning to have (more) children
in next 2 years 169 (9 %)
in >2 years 272 (14 %)
Not planning to have children 496 (26 %)
Not stated 145 (8 %)In the main, advice was given by hospital specialists
(Table 11). Fifty-eight percent of the women receiv-
ing advice stated that this was their main source of
information. General practitioners were mentioned by
a third. Of all the women who received advice, 17 %
were advised by the BEA (which might be expected in
this group of BEA members).
Overall, the women felt there was a need for more
information about epilepsy and pregnancy.
Menopause
Six hundred and twenty (34 %) of the women in the
study stated that they were either menopausal or post-
menopausal. One hundred and eighty-eight (30 %)
menopausal and post-menopausal women were cur-
rently taking hormone replacement therapy (HRT). A
further 97 (16 %) of the women had taken hormone
replacement therapy in the past.
Twenty-eight (29 %) women who had taken hormone
replacement therapy in the past reported an increase in
seizure frequency compared with 33 (18 %) amongst
current users (Table 12).
Discussion
Although a large number of women returned the
questionnaire, they were not wholly representative of
women with epilepsy. The women respondents tended
to have had a more severe seizure disorder in that only
34 % had well-controlled epilepsy. Community-basedaudit studies of epilepsy suggest that about 60 % of
women with a history of epilepsy are in remission and
are seizure-free1, 2. Fifty-nine percent of the women
who returned the questionnaire were currently being
followed-up in a hospital outpatient clinic compared
with 48 % from a recent community study1. Despite
this, many women in this study had received what they
perceived to be inadequate or no information about con-
traception or pregnancy in connection with their seizure
disorder. These are obviously issues of considerable
importance to women of childbearing age.
Despite knowledge for many years that the interac-
tions between the combined oral contraceptive pill and
enzyme-inducing antiepileptic drugs can lead to con-
traceptive failure, many doctors seem unaware of the
need to increase the dose of the contraceptive pill when
such drugs are prescribed together. A recent survey in
the USA showed that less than half of the neurologists
and obstetricians who replied knew that changes in the
dose of oral contraceptive pill might be indicated when
prescribing antiepileptic drugs in addition to an oral
contraceptive pill. Only 4 % of neurologists and none
of the obstetricians were correct in identifying the in-
teractions between the combined oral contraceptive pill
and phenytoin, carbamazepine, sodium valproate, phe-
nobarbitone, primidone and ethosuximide. Not surpris-
ingly, 27 % of neurologists and 21 % of obstetricians
reported contraceptive failures amongst their patients
taking antiepileptic drugs3.
In the last decade there have been several advances in
the management of women with epilepsy who wish to
have children. The most important of these has been the
advent of pre-conception counselling. It is recognized
that about 1 in 10 people labelled as having a seizure
disorder is incorrectly diagnosed. So when a woman
with epilepsy first sees a doctor to discuss starting a
family, it is important (as at other times) to reconsider
the diagnosis and to review drug therapy.
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Table 9: Advice given about pregnancy and epilepsy.
All women Women with children Plan to have children in
next 2 yrs >2 yrs
(n D 1855) (n D 880) (n D 169) (n D 272)
No advice 637 (34 %) 332 (38 %) 34 (20 %) 61 (22 %)
Not discussed with anyone 459 (25 %) 153 (17 %) 11 (7 %) 103 (38 %)
Any mention of the effects of
Medication 439 (23 %) 100 (11 %) 56 (33 %) 67 (25 %)
Teratogenicity 149 (7 %) 51 (5 %) 24 (15 %) 23 (12 %)
Other advice
To discuss with a doctor 158 (9 %) 34 (4 %) 31 (18 %) 58 (21 %)
Prepregnancy counselling 105 (6 %) 21 (2 %) 17 (10 %) 41 (15 %)
Folic acid supplements 87 (5 %) 42 (5 %) 34 (20 %) 22 (8 %)
Need for extra monitoring 26 (1 %) 14 (2 %) 8 (5 %) 5 (2 %)
Table 10: Concerns about pregnancy and childcare of women intending to have children in the subsequent 2 years.
No previous children Previous children
(n D 117) (n D 52)
Not given enough information 64 (55 %) 15 (28 %)
Unanswered questions about breast-feeding 68 (58 %) 22 (42 %)
Worried about effects of medication on unborn child 90 (77 %) 35 (68 %)
Anxious about increased seizures whilst pregnant 75 (64 %) 29 (56 %)
Worried about not being able to look after the child(ren) properly 33 (28 %) 7 (14 %)
Worried about whether they were able to have children because of epilepsy 28 (24 %) 7 (14 %)
Worried that their medication might affect their ability to have children 47 (40 %) 13 (25 %)
Table 11: Sources of advice.
All women Women with children Women planning to have a child in next 2 years
.n D 1885/ .n D 880/ .n D 169/
Hospital specialist 435 (23 %) 197 (22 %) 92 (54 %)
General practitioner 249 (13 %) 134 (15 %) 53 (31 %)
British Epilepsy Association 121 (7 %) 52 (6 %) 19 (11 %)
Friend/relative 31 (2 %) 9 (1 %) 2 (1 %)
Nurse 21 (1 %) 10 (1 %) 6 (4 %)
Media 20 (1 %) 6 (1 %) 2 (1 %)
Library 14 (1 %) 4 (0.5 %) 1 (0.5 %)
Found out own information 7 (0.5 %) 4 (0.5 %) 1 (0.5 %)
Table 12: Changes in seizure frequency amongst meno-
pausal and post-menopausal women.
Frequency of seizures Current users Past users Not used
of HRT of HRT HRT
(n D 188) (n D 97) (n D 335)
More frequent 33 (18 %) 28 (29 %) 51 (15 %)
Unchanged 54 (29 %) 28 (29 %) 57 (17 %)
Less frequent 39 (21 %) 12 (12 %) 76 (23 %)
Not stated 62 (33 %) 29 (30 %) 151 (45 %)One of the more important issues is that of antiepilep-
tic drug therapy. The risk of foetal malformation is
increased if a woman is on polytherapy, particularly
if sodium valproate is part of the combination. The
aim of drug therapy is to put the woman on the lowest
possible dosage of the most appropriate drug that will
control her seizures. All the older antiepileptic drugs
(carbamazepine, sodium valproate, phenytoin and bar-
biturates) are teratogenic in both humans and ani-
mals, showing similar patterns of malformation. Some
of the newer antiepileptic drugs such as lamotrigine,
gabapentin and tiagabine do not appear to be terato-
genic in animal studies, so in the future, these may
be the therapies of choice for women of childbearingage4. Data are currently being collected about newer
antiepileptic drugs and their safety in pregnancy5.
The genetics of the seizure disorder, breast-feeding
and issues of child care and epilepsy need to be
discussed. High dose folate supplements (5 mg) for
1 month before, and for the first 3 months of pregnancy
are recommended for women with epilepsy as there is a
high risk of spina bifida in the foetus exposed to carba-
mazepine or sodium valproate4. Very few of the women
respondents were aware of the need to take folic acid
before, and for the first 3 months after conception.
Over half the women who returned the questionnaire
felt that they had not been provided with enough infor-
mation about pregnancy; in particular, few had received
information about teratogenicity of antiepileptic drugs
or the need for pre-conception counselling.
There is very little information about epilepsy and the
menopause. In this study, in about a fifth of menopausal
and post-menopausal women, seizures became less fre-
quent. There are also scanty data relating to women
with epilepsy and HRT. Theoretically, treatment with
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Injury 1996; 27:97–100.oestrogens may increase seizure frequency in some
women with epilepsy6. The data from this study would
support this in that compared with women who had
not taken HRT, double the number of past users of
HRT reported an increase in seizure frequency at the
menopause. On the other hand, treatment with enzyme-
inducing antiepileptic drugs predisposes towards os-
teoporosis and osteomalacia. An increased incidence
of fractures has been reported, both related and un-
related to seizures7. It therefore seems sensible for a
menopausal woman to try HRT, but with the warning
that the HRT may exacerbate her seizure disorder. This
is an area which needs further research.
This study has shown that women with epilepsy want,
and need, far more information and counselling about
contraception, pregnancy and the menopause.
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